BOLT · Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics reported Q1 FY2026 results reflecting disciplined cost management post-October 2025 restructuring, which reduced overall operating expenses to preserve cash amid biotech's inherent clinical uncertainties. Revenue fell 97.9% to $26 thousand from $1.2 million in the prior year quarter, primarily due to limited activities with collaboration partners. This evaporation of collaboration revenue underscores the unpredictable timing of partner engagements, as management notes inability to forecast future arrangements or their impact on development plans and capital needs.

The operating loss improved 37.3% to -$7.6 million from -$12.1 million, driven by restructuring benefits including lower personnel-related expenses from workforce reduction and decreased consulting and professional services, partially offset by higher facility expenses. This operational leverage demonstrates effective execution of the cash preservation strategy announced in October 2025. Net loss followed suit, narrowing 34.4% to -$7.2 million from -$11.0 million, with diluted EPS at -$4.31 versus -$0.29 prior year, reflecting share dynamics amid persistent losses typical of clinical-stage biopharma.

Research and development expenses remain core to advancing product candidates, recognized as incurred with pre-payments capitalized until services received. Clinical trial processes are costly with uncertain timing, contributing to ongoing losses. General and administrative expenses will persist to support R&D and public company operations. Management continues monitoring macroeconomic factors' effects on results and condition, emphasizing resilience through cost controls while navigating collaboration dependencies and trial risks.